logo
Plus   Neg
Share
Email

NeuroRx, Relief, Quantum Leap To Include ZYESAMI In I-SPY COVID-19 Trial

NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (RLFTF) announced Monday that the companies signed a Clinical Trial Participation Agreement with Quantum Leap Healthcare Collaborative or QLHC for the inclusion of ZYESAMI (RLF-100: aviptadil) in the I-SPY COVID-19 Clinical Trial.

QLHC is the sponsor of the I-SPY COVID-19 Trial, a platform trial that is assessing multiple drugs for the treatment of patients with Critical COVID-19 who are hospitalized or in intensive care units.

ZYESAMI will be included as one of the first drugs targeting Respiratory Failure in critically ill COVID-19 patients.

The inclusion of ZYESAMI in the I-SPY COVID-19 Trial follows a request from the U.S. Department of Health and Human Services and the Department of Defense for investigational drugs capable of targeting the most acutely ill patients with COVID-19.

ZYESAMI has been granted Fast Track designation by the U.S. Food & Drug Administration for the treatment of Critical COVID-19 in patients with Respiratory Failure.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. said it is probing into the hack of its fourth-quarter earnings report that prompted the chipmaker to release its earnings statement ahead of schedule. The company, which was scheduled to release the results after the market closed, released it before the market closing on Thursday. Google parent Alphabet decided to drop its Internet balloon project Loon that was launched with the idea of providing Internet access to rural areas and providing last mile connectivity. In a blog post, Loon CEO Alastair Westgarth said they have not found a way to get the costs low enough to build a long-term, sustainable business, despite gaining a number of interested partners along the way. American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter.
RELATED NEWS
Follow RTT